CXCL12 and familial pancreatic carcinoma: Moreover, inhibition of C-X-C motif chemokine 12 (CXCL12) has been found to promote T cell accumulation and to act synergistically with checkpoint inhibitors, thus providing clinical benefits to patients with advanced stage pretreated metastatic colorectal and pancreatic cancer in a phase I/II trial6.